2023
DOI: 10.1016/j.hroo.2023.04.001
|View full text |Cite
|
Sign up to set email alerts
|

Electrographic flow–guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

3
1

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 23 publications
0
3
0
Order By: Relevance
“…43 The results from the completed randomized controlled clinical trial, FLOW-AF (NCT 04473963) that was designed to evaluate the effectiveness of EGF mapping for AF source detection and for targeting ablation therapy in persistent and long-standing persistent AF patients were recently presented and showed that EGF mapping and ablation resulted in successful elimination of sources in 95% of patients randomized to source ablation and that PVI with adjunctive EGF-guided source ablation improved AF free survival by 51% on an absolute basis at 1 year compared with PVI-only. 44,45…”
Section: Discussionmentioning
confidence: 99%
“…43 The results from the completed randomized controlled clinical trial, FLOW-AF (NCT 04473963) that was designed to evaluate the effectiveness of EGF mapping for AF source detection and for targeting ablation therapy in persistent and long-standing persistent AF patients were recently presented and showed that EGF mapping and ablation resulted in successful elimination of sources in 95% of patients randomized to source ablation and that PVI with adjunctive EGF-guided source ablation improved AF free survival by 51% on an absolute basis at 1 year compared with PVI-only. 44,45…”
Section: Discussionmentioning
confidence: 99%
“…The recently completed randomized controlled FLOW-AF study (NCT 04473963) was designed to assess the safety and feasibility of EGF mapping in patients with non-paroxysmal AF of duration <36 months (see Supplementary material online , Figure S1 ). 18 The present analysis includes the first 23 consecutive patients enrolled at a single centre between September 2019 and October 2020 and a total of 18 de novo patients who had never previously undergone catheter ablation for AF. FLOW-AF was approved by the Homolka Hospital Ethical Committee and Czech Regulatory Authority.…”
Section: Methodsmentioning
confidence: 99%
“…As described in the FLOW-AF Rationale & Design publication , a subset of patients in the FLOW-AF protocol were de novo persistent AF patients, never having previously undergone pulmonary vein isolation (PVI). 18 …”
Section: Methodsmentioning
confidence: 99%